iShares MSCI Taiwan ETF vs Medtronic PLC — how do they compare? iShares MSCI Taiwan ETF trades at $114.61 (market cap $12.74B), while Medtronic PLC trades at $87.75 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 8.8× iShares MSCI Taiwan ETF's market cap, and Medtronic PLC pays a 3.28% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Medtronic PLC for 63 Days on average.
| EWT | MDT | |
|---|---|---|
Market Cap | $12.74B | $112.24B |
Volume | 8,470,920 | 105,663,236 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $105.35 |
52-Week Low | $60.03 | $73.75 |
Typical Hold Time | 52 Days | 63 Days |
Enterprise Value | — | $131.58B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
EWT, the iShares MSCI Taiwan ETF, trades at $116.24, down 1.16% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF is heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights strong institutional interest and substantial Taiwanese corporate investments in U.S. AI infrastructure, though geopolitical tensions with China present ongoing risks.
The outlook for EWT is positive due to Taiwan's pivotal role in AI and semiconductor supply chains, supported by robust capital expenditure plans from key holdings. However, elevated geopolitical risks and sector concentration require careful monitoring. Upside potential hinges on sustained AI demand, while downside risks include cross-strait tensions and global tech volatility.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →